Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy

Next Previous
Trial Profile

A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; MCY-M11 (Primary)
  • Indications Adenocarcinoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man
  • Sponsors MaxCyte

    • Most Recent Events

    • 30 Aug 2021 Status changed from active, no longer recruiting to discontinued.
    • 22 Jan 2021 Status changed from recruiting to active, no longer recruiting.
    • 19 Aug 2020 Treatments section is updated with the addition of Intravenous Cyclophosphamide for pre-conditioning- this will be done in some patients of Cohorts 2,3 and 4 and those sub-groups within these cohorts are termed as-Cohort 2i, 3i and 4i respectively. Planned number of patients to be enrolled is increased from 15 to 27.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top